Anatara Lifesciences Ltd (ANR) - Total Liabilities
Based on the latest financial reports, Anatara Lifesciences Ltd (ANR) has total liabilities worth AU$612.42K AUD (≈ $433.33K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Anatara Lifesciences Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Anatara Lifesciences Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Anatara Lifesciences Ltd's total liabilities have evolved over time, based on quarterly financial data. See ANR free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Anatara Lifesciences Ltd Competitors by Total Liabilities
The table below lists competitors of Anatara Lifesciences Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AnalytixInsight Inc
V:ALY
|
Canada | CA$1.93 Million |
|
Goldcliff Resource Corp
V:GCN
|
Canada | CA$1.15 Million |
|
Lord Resources Ltd
AU:LRD
|
Australia | AU$191.42K |
|
Freight Technologies Inc
NASDAQ:FRGT
|
USA | $5.92 Million |
|
Northcliff Citranusa Indonesia Tbk PT
JK:SKYB
|
Indonesia | Rp7.94 Billion |
|
Australian Bond Exchange Holdings Ltd
AU:ABE
|
Australia | AU$6.83 Million |
|
Fram Skandinavien AB Series B
ST:FRAM-B
|
Sweden | Skr17.02 Million |
|
Beeks Trading Corporation Ltd
LSE:BKS
|
UK | GBX14.48 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Anatara Lifesciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Anatara Lifesciences Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anatara Lifesciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anatara Lifesciences Ltd (2011–2025)
The table below shows the annual total liabilities of Anatara Lifesciences Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$612.42K ≈ $433.33K |
+99.58% |
| 2024-06-30 | AU$306.85K ≈ $217.12K |
-37.99% |
| 2023-06-30 | AU$494.83K ≈ $350.13K |
+22.68% |
| 2022-06-30 | AU$403.35K ≈ $285.40K |
-18.79% |
| 2021-06-30 | AU$496.67K ≈ $351.43K |
+1.99% |
| 2020-06-30 | AU$486.96K ≈ $344.56K |
+4.33% |
| 2019-06-30 | AU$466.76K ≈ $330.26K |
-61.90% |
| 2018-06-30 | AU$1.22 Million ≈ $866.73K |
+314.62% |
| 2017-06-30 | AU$295.44K ≈ $209.04K |
-33.55% |
| 2016-06-30 | AU$444.62K ≈ $314.60K |
+202.51% |
| 2015-06-30 | AU$146.98K ≈ $104.00K |
-35.43% |
| 2014-06-30 | AU$227.62K ≈ $161.05K |
-35.51% |
| 2013-06-30 | AU$352.96K ≈ $249.74K |
+141.75% |
| 2012-06-30 | AU$146.00K ≈ $103.30K |
+630.00% |
| 2011-06-30 | AU$20.00K ≈ $14.15K |
-- |
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammat… Read more